The purpose of this study is to evaluate progression free survival and overall survival with the use of enzalutamide and rucaparib vs enzalutamide alone. You must be diagnosed with metastatic castration-resistant prostate cancer. This must be your first treatment for your metastatic cancer.
Contact phoneTracy Bellefeuil | 517.364.2835
Principal investigatorDr. Gordan Srkalovic, MD, PhD
Trial SubCategoryMetastatic Prostate